US promotion for Wyeth's Benefix is misleading, FDA says
This article was originally published in Scrip
A promotional flashcard for Wyeth's recombinant Factor IX product Benefix is misleading because it presents unsubstantiated superiority safety claims, the US FDAhas said. The flashcard suggests the recombinant nature of Benefix makes it safer than CSL Behring's plasma-derived Factor IV product Mononine for treating haemophilia B. "The overall presentation suggests that there is no viral risk associated with Benefix and that plasma-derived products such as Mononine are virally unsafe," the FDA said. Wyeth said it started using the flashcard in November but discontinued use last month before receipt of the FDA's violation letter. The company has responded to the agency and is making corrections to the promotion for future use.
You may also be interested in...
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Although US FDA wants sponsors to maintain blinded Phase III follow-up as long as possible after emergency use authorization or licensure, vaccine researcher Larry Corey says it will become ‘untenable’ to keep individuals in placebo arm once they qualify for vaccine access under the allocation framework.